A study by Kaushal et al. showed that antiRhoC siRNA led to decreased invasion, motility, and migration of the breast cancer cell lines SUM149 and MDA-MB-231, suggesting that RhoC is a potential therapeutic target [104]. This evidence concerns the gene RHOC and breast cancer.